arrhythmia (irregular heartbeat)

Distant relatedness in biobanks harnessed to identify undiagnosed genetic disease

VUMC researchers have developed a genetic method that clusters distantly related people to find rare variants that were present in a common ancestor.

Atrial Fibrillation Precision Research Program clinic team members arrange genetic testing for patients with AFib. (photo by Erin O. Smith)

Program arranges genetic testing for AFib patients who may be at risk for inherited cardiomyopathy or arrhythmia syndromes

Without treatment, younger patients may develop other serious cardiac disorders such as heart failure or life-threatening ventricular arrhythmias.

Targeting calcium handling in A-fib

The drug ent-verticilide reduced A-fib incidence and duration in an animal model, suggesting it may be a viable therapeutic option.

Preempting sudden cardiac death

A technique to characterize all variants in genes associated with arrhythmia could improve the ability to identify and preemptively treat individuals at risk for sudden cardiac death.

A clue to an adverse drug event in children

Considering metabolic (CYP2D6) enzyme activity score and patient age may aid in determining an individual’s risk for an adverse event with administration of the anti-arrhythmic drug propafenone.

Studies by Andrew Glazer, PhD, Giovanni Davogustto, MD, and colleagues found that genetic testing with information from electronic health records can reveal undiagnosed heart rhythm disorders.

Studies combine genetic testing, electronic health records to find undiagnosed diseases

Combining genetic testing with information from electronic health records revealed undiagnosed heart rhythm disorders and new conditions associated with inherited cancer gene mutations.

1 2